07/22/2025

Therapeutic Peptides: Importance, Challenges, and Bioanalysis by LC-MS/MS

SHARE

Therapeutic peptides are highly specific and efficacious molecules, attractive for treating diseases like diabetes, obesity, and cancer. Although historically analyzed by ligand-binding assays, LC-MS/MS now provides superior selectivity and specificity. However, several challenges remain, such as peptide stability, solubility, and non-specific binding, which should be solved during the development of the analytical method. Anapharm Bioanalytics supports peptide drug development through rigorous LC-MS/MS bioanalysis, comprehensive method validation, and GLP compliance. While Anapharm has experience with established peptides such as semaglutide, liraglutide, exenatide, octreotide, etc., it routinely works on the bioanalysis of novel, custom-designed peptides, ensuring accurate quantification and regulatory adherence from discovery to clinical trials.

What makes therapeutic peptides an attractive tool?

Peptides influence many physiological processes that have an impact on the endocrine, nervous, and immune systems, among others. Their mechanism of action is linked to the ability to regulate gene expression and protein synthesis. Because of this characteristic, therapeutic peptides are considered a promising tool for treating conditions such as cancer, diabetes, and cardiovascular diseases. Commercially available peptide-based therapeutics include the agonists of the glucagon-like peptide-1 (GLP-1) receptor, liraglutide, and semaglutide, which are currently used for weight loss and to regulate blood sugar levels.
Compared to small-molecule therapeutics, in general, peptides exhibit higher specificity and efficacy. Peptides also tend to cause lower toxicity and, unlike therapeutic proteins, do not trigger strong immune responses. This translates into fewer adverse effects and greater safety. Moreover, peptides are cheaper to produce than large biologics.
Another important key feature of therapeutic peptides is the high degree of customization. For instance, liraglutide and semaglutide have been modified to improve their half-life and consequently increase the time between administrations. In addition to improving its stability, peptides can be modified to deliver specific payloads into the cell. All these features combined highlight the potential of therapeutic peptides as versatile tools in drug development.

Historical background of the use of peptides as therapeutics:

In 1923, Banting and MacLeod received the Nobel Prize in Physiology or Medicine for the discovery of insulin. In the same year, insulin became the first therapeutic peptide to be marketed. Currently, a large number of different peptide-based therapeutics have been approved, and demand has skyrocketed, partly due to the development of glucagon-like peptides as a revolutionary treatment for obesity and diabetes.
Historically, peptides have been analyzed by ligand binding techniques. These bioanalytical assays suffer from antibody cross-reactivity, while they do not provide structural insight into metabolites or modifications. Technological advances have shifted interest to LC-MS/MS, as this technique delivers both better fragment selectivity and specificity.

Challenges in LC-MS/MS bioanalysis of peptide-based therapeutics:

Therapeutic peptides are a diverse group of molecules, each presenting unique analytical challenges:

• Peptides usually have lower analytical sensitivity than small molecules due to their multiple charge states, high polarity, and size.
• Ensuring peptide stability during the bioanalytical process is challenging, as peptides are susceptible to enzymatic (proteolysis) and chemical (hydrolysis) degradation.
• Peptides often face solubility issues in standard buffers, leading to high variability between samples.
• Non-specific binding to labware (e.g., tubes, pipette tips) can result in analyte losses and instrumental carryover.
• Method validation for GLP environments is significantly more demanding due to all the above factors.

Anapharm Bioanalytics Can Support Your Peptide Drug Development Journey

At Anapharm, we understand the complexities of peptide drug development. Our experienced team of scientists and managers is here to support you at every stage of your project.

• Comprehensive support from early discovery through GLP-compliant clinical trials.
• Advanced bioanalytical services for LC-MS/MS peptide analysis, including pharmacokinetic studies at very low quantitation limits
• Extensive experience in managing challenges across a wide range of therapeutic peptides.
• Scientific and regulatory guidance to keep your project on track and compliant.
• Expertise in developing and validating fully GLP-compliant bioanalytical assays.

Our commitment to quality and regulatory excellence has made us a trusted partner in therapeutic peptide development. We work closely with you to ensure your peptide drugs are analyzed with precision and meet all regulatory standards.

Looking for readily available bioanalytical methods to support your studies? You can check out our bioanalytical method list.

References
https://pmc.ncbi.nlm.nih.gov/articles/PMC8619776/
https://pmc.ncbi.nlm.nih.gov/articles/PMC10609221/#sec2-molecules-28-07165
https://pubmed.ncbi.nlm.nih.gov/34766279/